TAIPEI, July 28, 2022 /PRNewswire/ — Cellular visiona startup based in Taiwanhas developed a SACA monitoring system that can improve patient survival rates from the dangers of cancer, as well as improvements in reproductive medicine. The company recently participated in the VivaTech 2022 event in Paris, France show their product to other startups and leaders and demonstrate the company’s innovative cancer prediction technology.

Although the effectiveness of cancer treatment varies from individual to individual, with generally higher overall recurrence rates, it is important for patients to understand their condition and what can be done for treatment. The Cell Envision SACA system actively monitors the likelihood of recurrence, giving patients the opportunity to seek active treatment early and increasing their chances of overcoming the disease.

The SACA system, which uses a variety of technologies including a non-fixable live-cell staining microdialysis chip and a patient-derived explant platform used for profiling, enables more efficient evaluation and selection of the response for cancer immunotherapy.

Using multi-omics analytical modules makes it easy to detect somatic mutation profiles, build a full immune profile, and even produce cell therapy predictions that can be accurate for most information. When it comes to capturing a specific target cell, using these systems makes the process much more efficient.

Cell Envision SACA monitoring system features include:

• Liquid biopsy – Only 2 ml of blood is needed for the analysis
• Simultaneous analysis of multiple types of cancer cells – Circulating tumor cancer cells, cancer cell clusters, immune cells and conjugated cancer cells, etc. can be analyzed
• High Accuracy – Predicted success rate is 8 times higher than CEA or CA 199 monitoring alone
• Ease of use – Cancer cells can be isolated on the genetic testing platform

Pushing the boundaries of biotechnology, Cell Envision aims to accelerate the discovery of identification and pathogenesis in reproductive medicine and oncology by revealing the functional biology of every patient cell, and SACA system monitors will help open the way.

With patents approved in United States, Chinaand Taiwan, Cell Envision hopes to deliver even more positive results in the field of biotechnology. The company recently closed its angel funding round and will be looking to new territories like Europe and United States following his presence in Asia.

With the support of the Ministry of Science and Technology (MOST), the company is in a great position to further innovate and bring even more benefits to medical players and patients around the world.

About Cell Envision

We are the first commercial patient-derived explant (PDE) platform used to profile cancer immunotherapy response assessment and selection by developing single-cell functional multi-omics analytical modules with system SACA monitoring. Cellenvision accelerates the discovery of identification and pathogenesis in oncology by revealing the true functional biology of each patient cell.

SOURCE Cell Vision